Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol

BACKGROUND: The intensive study of predictive factors has strongly ameliorated the therapeutic flow-chart of metastatic colorectal cancer (mCRC) by allowing the selection of patients who benefit from specific therapies. For instance, in mRAS (mutated RAS) mCRC patients, anti-EGFR drugs (cetuximab an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Ottaiano, Alessandro, Scala, Stefania, Santorsola, Mariachiara, Trotta, Anna Maria, D’Alterio, Crescenzo, Portella, Luigi, Clemente, Ottavia, Nappi, Anna, Zanaletti, Nicoletta, De Stefano, Alfonso, Avallone, Antonio, Granata, Vincenza, Notariello, Carmen, Luce, Amalia, Lombardi, Angela, Picone, Carmine, Petrillo, Antonella, Perri, Francesco, Tatangelo, Fabiana, Di Mauro, Annabella, Albino, Vittorio, Izzo, Francesco, Rega, Daniela, Pace, Ugo, Di Marzo, Massimiliano, Chiodini, Paolo, De Feo, Gianfranco, Del Prete, Paola, Botti, Gerardo, Delrio, Paolo, Caraglia, Michele, Nasti, Guglielmo
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2021
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8010802/
https://ncbi.nlm.nih.gov/pubmed/33854566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835921989223
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados